Helius Medical Technologies (Helius Medical Technologies) Long-Term Capital Lease Obligation : $0.01 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies Long-Term Capital Lease Obligation?

Helius Medical Technologies's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil.

Helius Medical Technologies's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.04 Mil) to Sep. 2023 ($0.02 Mil) and declined from Sep. 2023 ($0.02 Mil) to Dec. 2023 ($0.01 Mil).

Helius Medical Technologies's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.06 Mil) but then declined from Dec. 2022 ($0.06 Mil) to Dec. 2023 ($0.01 Mil).

Helius Medical Technologies Long-Term Capital Lease Obligation Historical Data

The historical data trend for Helius Medical Technologies's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helius Medical Technologies Long-Term Capital Lease Obligation Chart

Helius Medical Technologies Annual Data

Trend

Mar14

Mar15

Mar16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.47

0.03

0.06

0.01

Helius Medical Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.06	0.05	0.04	0.02	0.01

Helius Medical Technologies (NAS:HSDT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Helius Medical Technologies Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Helius Medical Technologies (Helius Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (NAS:HSDT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940

Website

https://www.heliusmedical.com

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Executives

Dane Andreeff	director, 10 percent owner, officer: President and CEO	C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459
Jeffrey S Mathiesen	director, officer: CFO and Treasurer	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Favit-van Pelt Antonella R.	officer: Chief Medical Officer	C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Sherrie L Perkins	director	5033 TANGLE LANE, HOUSTON TX 77056
Jennifer Laux	officer: Chief Commercial Officer	642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940
Thomas E Griffin	director	C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Blane Walter	director	500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082
Edward M Straw	director	C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153
Joyce N Laviscount	officer: See Remarks	100 ENDO BOULEVARD, CHADDS FORD PA 19317
Huaizheng Peng	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Philippe Deschamps	director, 10 percent owner, officer: President & CEO	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Mitch E Tyler	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Jonathan Sackier	10 percent owner, officer: Chief Medical Officer	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
A&b (hk) Co Ltd	10 percent owner	8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057